Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthonius de Boer

Showing results (11-20 of 308) with videos related to

Pageof 31
Sort By:
AIDS Care|October 1, 2008
Comparison of knowledge and accessibility to information sources of HIV/AIDS between blind and sighted populations in NigeriaWillem M Otte, Frank van der Maas, Anthonius de Boer
British Journal of Clinical Pharmacology|August 2, 2019
Measuring the impact of pharmacovigilance activities, challenging but importantFlorence van Hunsel, Helga Gardarsdottir, Anthonius de Boer, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 28, 2010
Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugsKim Taverne, Mark de Groot, Anthonius de Boer, et al.
Archives of Internal Medicine|January 30, 2008
Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarinsTom Schalekamp, Olaf H Klungel, Patrick C Souverein, et al.
Pharmacoepidemiology and Drug Safety|April 4, 2017
Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control studyMohammad Bakhriansyah, Patrick C Souverein, Anthonius de Boer, et al.
Journal of Clinical Pharmacy and Therapeutics|April 9, 2019
Risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs: Impact of additional confounding control for variables collected from self-reported dataMohammad Bakhriansyah, Patrick C Souverein, Anthonius de Boer, et al.
Health Policy (Amsterdam, Netherlands)|December 3, 2014
A comparative study of the role of disease severity in drug reimbursement decision making in four European countriesMargreet Franken, Elly Stolk, Tessa Scharringhausen, et al.
Pharmacoeconomics|July 11, 2013
Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision makingMargreet Franken, Fredrik Nilsson, Frank Sandmann, et al.
Thrombosis and Haemostasis|January 10, 2009
Effect of oral antiplatelet agents on major bleeding in users of coumarinsTom Schalekamp, Olaf H Klungel, Patrick C Souverein, et al.
Thrombosis and Haemostasis|August 12, 2008
Pharmacogenomics of coumarin anticoagulants: are we underestimating the role of CYP2C9?Tom Schalekamp, Anke-Hilse Maitland-van der Zee, Anthonius de Boer
Pageof 31

Showing results (11-20 of 308) with videos related to

Sort By:
Pageof 31
AIDS Care|October 1, 2008
Comparison of knowledge and accessibility to information sources of HIV/AIDS between blind and sighted populations in NigeriaWillem M Otte, Frank van der Maas, Anthonius de Boer
British Journal of Clinical Pharmacology|August 2, 2019
Measuring the impact of pharmacovigilance activities, challenging but importantFlorence van Hunsel, Helga Gardarsdottir, Anthonius de Boer, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 28, 2010
Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugsKim Taverne, Mark de Groot, Anthonius de Boer, et al.
Archives of Internal Medicine|January 30, 2008
Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarinsTom Schalekamp, Olaf H Klungel, Patrick C Souverein, et al.
Pharmacoepidemiology and Drug Safety|April 4, 2017
Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control studyMohammad Bakhriansyah, Patrick C Souverein, Anthonius de Boer, et al.
Journal of Clinical Pharmacy and Therapeutics|April 9, 2019
Risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs: Impact of additional confounding control for variables collected from self-reported dataMohammad Bakhriansyah, Patrick C Souverein, Anthonius de Boer, et al.
Health Policy (Amsterdam, Netherlands)|December 3, 2014
A comparative study of the role of disease severity in drug reimbursement decision making in four European countriesMargreet Franken, Elly Stolk, Tessa Scharringhausen, et al.
Pharmacoeconomics|July 11, 2013
Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision makingMargreet Franken, Fredrik Nilsson, Frank Sandmann, et al.
Thrombosis and Haemostasis|January 10, 2009
Effect of oral antiplatelet agents on major bleeding in users of coumarinsTom Schalekamp, Olaf H Klungel, Patrick C Souverein, et al.
Thrombosis and Haemostasis|August 12, 2008
Pharmacogenomics of coumarin anticoagulants: are we underestimating the role of CYP2C9?Tom Schalekamp, Anke-Hilse Maitland-van der Zee, Anthonius de Boer
Pageof 31